STAT

Pregnant women who need medications face a risky guessing game. A federal task force is now trying to help

Congress last year created an NIH task force to study why women can't get reliable answers on medication use during pregnancy — and to recommend solutions.

So many women face wrenching decisions about using medication during their pregnancies. Now, federal officials are finally inviting them to tell their stories. And they’re not holding back:

“I was on Zoloft for many years before I became pregnant with my first. Both my psychiatrist and OB/GYN would not give me an answer about if I should continue to take it.”

“For every condition that couldn’t be addressed with acetaminophen or antacids, I was out of luck. Several months later, when I forgot to take that list of medications on vacation with me and came down with a cold, I sweated bullets trying to recall whether medicated cough drops had been on the list.”

“I wish I came off the meds while I was pregnant but what was done was done.”

Their fears and frustrations are slowly stirring change. Congress last year created a task force through the National Institutes of Health to study why so few women can get reliable answers on medication use during pregnancy — and to recommend solutions. Members have been holding public meetings and reviewing the women’s comments. Experts say it’s long overdue.

Few drugs have been approved as safe and effective to use during pregnancy, and most of those are for conditions specific to pregnancy. As a result, almost every medicine given to a pregnant woman, from prescription antacids for acid reflux to biologic drugs to prevent epileptic seizures, is considered an off-label use. Some doctors

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks